| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2022-09-27 |
| タイトル |
|
|
タイトル |
Evaluation of the Utility of Angiotensin Receptor Blockers for Renal Protection in Japanese Renal Allograft Recipients |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
renal transplantation |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hypertension |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
angiotensin II receptor blockers |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
monocyte chemoattractant protein-1 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.57457/00000008 |
|
ID登録タイプ |
JaLC |
| 著者 |
大串 勇気
沖野 一晃
向井 清孝
林 憲史
藤本 圭司
足立 浩樹
古市 賢吾
横山 仁
|
| 著者（英） |
|
|
|
姓名 |
Yuki Okushi |
|
|
言語 |
en |
| 著者（英） |
|
|
|
姓名 |
Kazuaki Okino |
|
|
言語 |
en |
| 著者（英） |
|
|
|
姓名 |
Kiyotaka Mukai |
|
|
言語 |
en |
| 著者（英） |
|
|
|
姓名 |
Norifumi Hayashi |
|
|
言語 |
en |
| 著者（英） |
|
|
|
姓名 |
Keiji Fujimoto |
|
|
言語 |
en |
| 著者（英） |
|
|
|
姓名 |
Hiroki Adachi |
|
|
言語 |
en |
| 著者（英） |
|
|
|
姓名 |
Kengo Furuichi |
|
|
言語 |
en |
| 著者（英） |
|
|
|
姓名 |
Hitoshi Yokoyama |
|
|
言語 |
en |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Introduction: The beneficial effects of angiotensin receptor blockers (ARB), particularly the differential effects of their subclasses, on renal transplant recipients currently remain unclear. Therefore, we herein investigated the effects of irbesartan and losartan on graft function in a single center cohort of renal allograft recipients.
Methods: Seventy-nine Japanese renal allograft recipients with hypertension were enrolled in the present study. They were randomly divided into two groups based on their demographic factors and were given irbesartan (50-100 mg/day; Group Ir, n=35) or losartan (25-50 mg/day; Group L, n=37). During the study period, the dosage was adjusted to control blood pressure (BP) levels. Physiological and biochemical parameters were measured before and after the 48-week study period.
Results: The administration of ARB was successfully maintained throughout the 48-week study period in 28 patients in Group Ir (70%) and 32 patients in Group L (82.1%). Mean BP significantly decreased from 94.7 to 91.2 (-3.5) mmHg in Group L and from 96.6 to 91.3 (-5.4) mmHg in Group L (p=0.047 and p=0.003, respectively). Changes in the estimated glomerular filtration rate (ΔeGFR) were observed in both groups (-2.8 and -1.7 mL/min/1.73m2/year, respectively). No significant differences in albuminuria or serum creatinine or urinary MCP-1 levels were detected among the groups. A sub-analysis of the treatment (Tx) patterns of ARB revealed that eGFR was stable in a subgroup with continuous ARB Tx, but decreased in other subgroups without ARB and add-on ARB. Reductions in albuminuria were significantly greater for add-on ARB than in the other groups (p=0.004).
Discussion/Conclusion: Irbesartan and losartan both decreased BP in Japanese renal allograft recipients with hypertension. Newly administered ARB, including irbesartan and losartan, significantly decreased BP and albuminuria. Long-term ARB therapy may improve the outcomes of renal allografts. |
| 書誌情報 |
金沢医科大学雑誌
en : Journal of Kanazawa Medical University
巻 46,
号 1,
p. 7-18,
発行日 2021-06
|
| 出版者 |
|
|
出版者 |
金沢医科大学医学会 |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0385-5759 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
本文 (1.4 MB)
